Chengdu Kanghong Pharmaceutical Group

Name

Chengdu Kanghong Pharmaceutical Group

Legal name

Chengdu Kanghong Pharmaceutical Group Co., Ltd

Website

https://cnkh.com

Company type

Public

Founded year

1996

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Product category

Pharmaceuticals (Biologics, TCM, and Chemical Drugs)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Ophthalmology Pharmaceuticals (HLAIAAAL)

akta.pro secondary industries

Specialty Care Pharmaceuticals (HLAIAAAB), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Ophthalmic biologics
• Traditional Chinese medicine
• Chemical drug manufacturing
• Gene therapy products
• Innovative pharmaceuticals

Headquarters

HQ city

Chengdu

HQ country

China

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Revenue from manufacturing and selling prescription pharmaceutical products including biological drugs, traditional Chinese medicines, and chemical drugs across therapeutic areas including ophthalmology, CNS, cardiovascular, respiratory, and digestive systems.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Chengdu Kanghong Pharmaceutical Group is a vertically integrated pharmaceutical company that researches, develops, manufactures, and commercializes innovative biological drugs, traditional Chinese medicines (TCM), chemical drugs, and active pharmaceutical ingredients across ophthalmology, CNS/psychiatry, cardiovascular, respiratory, and digestive therapeutic areas. Its flagship offering, Conbercept ophthalmic injection (brand Lumitin/朗沐), is the first Chinese-origin Class 1 biologic for wet age-related macular degeneration. The company also markets 25 finished pharmaceutical products, operates a pipeline of gene therapies, dual-payload ADCs, and synthetic-biology oncology candidates, and sells APIs through certified NMPA, EMA, and FDA cGMP-compliant facilities.

Product overview

Chengdu Kanghong Pharmaceutical Group (stock: 002773) is a publicly traded pharmaceutical company founded in 1996, specializing in the R&D, manufacturing, and distribution of biologics, TCM preparations, chemical drugs, and medical devices. The company operates an integrated business model combining innovation-driven drug development with standardized production facilities and nationwide marketing networks. The product portfolio spans four major therapeutic areas: Ophthalmology (including Lumitin/Conbercept Ophthalmic Injection - the first Chinese original Class 1 biologics to receive WHO INN), CNS/Psychiatry (including Shuganjieyu - China's first approved TCM for depression, plus multiple generic chemical drugs), Cardiovascular (including Songling Xuemaikang for hypertension and hyperlipidemia), and Digestive/Respiratory/Other areas (including TCM preparations and prokinetic agents). The company also produces Active Pharmaceutical Ingredients (APIs) and operates an R&D pipeline including gene therapy products (KH631, KH658, KHN921), ADC drugs (KH815, KHN922), and synthetic biology products (KH617). As of 2025, the company has 25 marketed pharmaceutical products, with 10 exclusive varieties, 20 products included in the National Reimbursement Drug List, and 11 in the National Essential Medicines List. The company maintains high R&D investment with 324 authorized patents (264 invention patents) as of December 2025.

Differentiator

Problem solved

Functional benefit

Brands

• 朗沐 (Lumitin): Brand name for Conbercept Ophthalmic Solution, flagship ophthalmology product for wet age-related macular degeneration
• 舒肝解郁胶囊 (Shuganjieyu)
• 济生堂 (Jishengtang)

Products and services

• Conbercept Ophthalmic Injection (康柏西普眼用注射液, brand 朗沐/Lumitin) Recombinant fusion protein (anti-VEGF) produced in CHO cells for ophthalmology; approved for neovascular AMD, diabetic macular edema, macular edema secondary to RVO, and choroidal neovascularization from pathologic myopia; first Chinese-origin Class 1 biologic to receive a WHO INN; administered to patients in Chinese hospital ophthalmology departments.
• Shuganjieyu Capsules (舒肝解郁胶囊)

Quantifiable outcome

• Over 5 million patient injections completed for 康柏西普眼用注射液 in 11 years
• +3 more outcomes

Named customers3 records

Segments1 record

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• BioDlinkcoreTechnology or Integration · 9 February 2026BioDlink served as Kanghong's CDMO partner for KH815, the world's first dual-payload ADC. BioDlink completed process development, manufacturing, and regulatory submission activities 1.5 months ahead of schedule for IND approval of KH815. Recognized by Kanghong with formal letter of appreciation for enabling the world's first dual-payload ADC to enter clinical development.

Scale indicators7 records

Recent moves7 records

Expansion highlights4 records

Broad incumbents

• Roche Holding: Global pharmaceutical incumbent whose Lucentis (ranibizumab) and Avastin (bevacizumab) compete with Conbercept in ophthalmology. Relevant for benchmarking anti-VEGF market dynamics and Kanghong's potential international expansion headwinds.
• Regeneron Pharmaceuticals: US biopharmaceutical company (NASDAQ: REGN) whose Eylea (aflibercept) directly competes with Conbercept in the global anti-VEGF ophthalmology market. Most relevant international incumbent peer for benchmarking Kanghong's flagship franchise.

Direct peers

• Hansoh Pharmaceutical Group: Hong Kong-listed Chinese innovative pharma (HKEX: 3692) with CNS, oncology and anti-infective franchises. Directly comparable in CNS product overlap (antipsychotics, antidepressants) and pursuit of branded innovative drugs in China.
• Innovent Biologics: Chinese biopharmaceutical company (HKEX: 1801) focused on innovative biologics including monoclonal antibodies and ADCs. Directly comparable in biologics manufacturing capability and pursuit of oncology biologics similar to Kanghong's KH815/KHN922 dual-payload ADCs.
• CSPC Pharmaceutical Group: Hong Kong-listed Chinese pharma (HKEX: 1093) with innovative drugs, biologics, and TCM. Competes in similar hospital-channel distribution in China and is pursuing oncology and CNS pipelines that overlap Kanghong's therapeutic mix.
• Jiangsu Hengrui Pharmaceuticals: Largest Chinese innovative pharmaceutical company (SHA: 600276), similarly building a pipeline of branded biologics, chemical drugs and specialty therapeutics across oncology, CNS and other areas. Comparable in scale, multi-platform R&D model, and Chinese-domestic commercialization focus.
• Sichuan Kelun Pharmaceutical: Sichuan-based Chinese pharmaceutical manufacturer (SHE: 002422) with overlapping geographic base, infusion and injectable capabilities, and a portfolio spanning CNS, anti-infectives, and nutrition. Comparable scale and China-domestic distribution model.
• Shanghai Fosun Pharmaceutical: Diversified Chinese pharmaceutical group (SHA: 600196; HKEX: 2196) operating across pharmaceutical manufacturing, distribution, medical devices, and healthcare services. Comparable in integrated pharma model spanning biologics, chemical drugs, TCM and devices.

Emerging players

• BeiGene: Chinese oncology biotech (NASDAQ: BGNE; HKEX: 6160) developing innovative cancer therapies including biologics. Comparable in pursuit of frontier oncology modalities from a Chinese R&D base, though more oncology-specialized.

Others

• WuXi Biologics: Chinese biologics CDMO (HKEX: 2269) with global scale in mammalian cell culture and ADC manufacturing. Relevant ecosystem peer given Kanghong's outsourced relationship with BioDlink for KH815 and its broader biologics manufacturing needs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xweibo.com/u/2988031811
• LinkedInlinkedin.com/company/chengdu-kanghong-pharmaceutical-group

Compliance18 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chengdu Kanghong Pharmaceutical Group